Emerging trends in post-translational modification: Shedding light on Glioblastoma multiforme

Kumari, Smita; Gupta, Rohan; Ambasta, Rashmi K.; Kumar, Pravir

doi:10.1016/j.bbcan.2023.188999

Cited by 3 publications

(1 citation statement)

References 290 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTMs play a central role in a wide range of biological processes, including cell signaling pathway, immune response, DNA damage response, and metabolism ( 3 , 4 ). Dysregulation of PTMs is associated with various diseases, including cancer ( 5 – 7 ), neurodegenerative disorders ( 8 , 9 ), cardiovascular diseases ( 10 ), and metabolic syndromes ( 11 , 12 ). It is critical to explore the regulatory mechanism of PTMs in order to discover the new targets for disease treatments.…”

Section: Introductionmentioning

confidence: 99%

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy

Ren,

Wang,

Liu

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Immunotherapy has been developed, which harnesses and enhances the innate powers of the immune system to fight disease, particularly cancer. PD-1 (programmed death-1) and PD-L1 (programmed death ligand-1) are key components in the regulation of the immune system, particularly in the context of cancer immunotherapy. PD-1 and PD-L1 are regulated by PTMs, including phosphorylation, ubiquitination, deubiquitination, acetylation, palmitoylation and glycosylation. PROTACs (Proteolysis Targeting Chimeras) are a type of new drug design technology. They are specifically engineered molecules that target specific proteins within a cell for degradation. PROTACs have been designed and demonstrated their inhibitory activity against the PD-1/PD-L1 pathway, and showed their ability to degrade PD-1/PD-L1 proteins. In this review, we describe how PROTACs target PD-1 and PD-L1 proteins to improve the efficacy of immunotherapy. PROTACs could be a novel strategy to combine with radiotherapy, chemotherapy and immunotherapy for cancer patients.

show abstract